Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP8 | P22894 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22879281 | 1.00 | ALDH1A1 (0.40) | ALDH1A1ACHEKMT2ATHRBMEN1 | |
| SCHEMBL19682937 | 1.00 | ALDH1A1 (0.40) | ALDH1A1ACHEKMT2ATHRBMEN1 | |
| SCHEMBL19490021 | 1.00 | ALDH1A1 (0.40) | ALDH1A1ACHEKMT2ATHRBMEN1 | |
| SCHEMBL21655703 | 1.00 | ALDH1A1 (0.40) | ALDH1A1ACHEKMT2ATHRBMEN1 | |
| SCHEMBL21335755 | 0.97 | ALDH1A1 (0.42) | ALDH1A1KMT2ATHRBMEN1 | |
| SCHEMBL21968004 | 0.97 | ALDH1A1 (0.42) | ALDH1A1KMT2ATHRBMEN1 | |
| SCHEMBL21335754 | 0.97 | ALDH1A1 (0.42) | ALDH1A1ACHEKMT2ATHRBMEN1 | |
| SCHEMBL22385134 | 0.97 | ALDH1A1 (0.42) | ALDH1A1ACHEKMT2ATHRBMEN1 | |
| SCHEMBL21577837 | 0.97 | ALDH1A1 (0.42) | ALDH1A1ACHEKMT2ATHRBMEN1 | |
| SCHEMBL19490020 | 0.95 | ALDH1A1 (0.37) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349580-A1 | DIHYDROINDOLIZINONE DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349580-A1 | DIHYDROINDOLIZINONE DERIVATIVE | CYP2C19, CYP4A22, CYP4A11 | ALDH1A1 1113/4885ACHE 1934/4885KMT2A 2504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.